electroCore, Inc.

electroCore, Inc. is a commercial-stage bioelectronic technology company dedicated to improving health and quality of life through innovative non-invasive bioelectronic technologies. The company's mission is to help patients globally who suffer from pain and chronic conditions by harnessing the power of non-invasive vagus nerve stimulation (nVNS), innovation, and technology to develop safe and clinically backed treatments. Its global headquarters are located in Rockaway, New Jersey, USA.

The company's key product portfolio includes gammaCore, a prescription handheld device cleared by the FDA for the acute and preventive treatment of primary headache disorders such as migraine and cluster headache. Additionally, electroCore offers Quell Fibromyalgia, a neurostimulator for chronic pain syndromes, and commercializes personal-use consumer products like Truvaga and TAC-STIM, which utilize nVNS technology for general wellness and human performance. electroCore operates across prescription medical devices, direct-to-consumer wellness, and government/military market segments, with a presence in the United States, the United Kingdom, Japan, and other international regions.

In recent news, electroCore reported record full-year 2025 net sales of $32.0 million, representing approximately 27% year-over-year growth. The company announced that CEO Dan Goldberger would retire on April 1, 2026, with Joshua Lev appointed as interim President and Michael Fox hired as Chief Operating Officer. Further demonstrating its innovation, electroCore's TAC-STIM product was named a national semifinalist in the National Safety Council 2026 Work to Zero Safety Innovation Challenge in April 2026, and the company expanded its intellectual property portfolio with new U.S. patents in early 2026.

Latest updates

electroCore's Fatigue-Fighting Tech Advances in National Safety Challenge

Event summary

  • electroCore's TAC-STIM, a non-invasive vagus nerve stimulation device, is a national semifinalist in the 2026 Work to Zero Safety Innovation Challenge.
  • The challenge focuses on technologies addressing workplace fatigue, a recognized safety risk.
  • TAC-STIM was developed in partnership with the U.S. Air Force Research Laboratory.
  • Semifinalists will present at the NSC Safety Summit on May 7th and 8th, 2026, for potential finalist selection and grant eligibility.
  • TAC-STIM is currently deployed across multiple branches of the U.S. military.

The big picture

The NSC’s Work to Zero Challenge highlights the growing recognition of fatigue as a critical workplace safety issue, particularly in industries with high-risk environments. electroCore's TAC-STIM positions the company to capitalize on this trend, but its success hinges on demonstrating tangible results and securing broader adoption beyond its existing military contracts. The company's broader bioelectronic portfolio, while including prescription therapies, is increasingly focused on wellness and human performance, a market segment with significant, albeit competitive, growth potential.

What we're watching

Pilot Program
The success of electroCore’s application for the Work to Zero Pilot Grant Program will be a key indicator of broader market adoption and potential revenue streams beyond existing military contracts.
Military Spending
Continued government funding and adoption of TAC-STIM within the U.S. military will remain crucial, as these contracts represent a significant portion of current revenue.
Commercialization
The pace at which electroCore can expand TAC-STIM’s commercial applications beyond military and government use will determine its long-term growth potential and ability to diversify revenue streams.

electroCore Executives to Address Investors Amidst Bioelectronic Medicine Scrutiny

Event summary

  • electroCore executives, including Interim President and CFO Joshua Lev, will present at the Market Movers Investor Summit on May 5, 2026.
  • The summit, held at 48 Wall Street in New York City, features presentations, one-on-one meetings, and keynote sessions for executives and investors.
  • electroCore’s products include gammaCore® (nVNS), Quell® (neurostimulator), Truvaga™ and TAC-STIM™ (nVNS).
  • The Market Movers Investor Summit begins May 4th with a kickoff party at Delmonico’s.

The big picture

electroCore operates in a nascent bioelectronic medicine sector attracting increasing investor interest, but also facing scrutiny regarding efficacy and reimbursement. The Market Movers Investor Summit provides a key opportunity for the company to address investor concerns and articulate its growth strategy amidst a broader trend of non-invasive therapeutic approaches. The summit’s format, including one-on-one meetings, suggests a targeted effort to engage with key fund managers and family offices.

What we're watching

Leadership Transition
The presence of an Interim CFO suggests ongoing instability within the executive team, and the summit presentation will be scrutinized for clarity on the search for a permanent replacement and the impact on strategic direction.
Commercial Traction
Given the company’s focus on both prescription and consumer wellness products, the summit will reveal whether electroCore can demonstrate sustainable revenue growth across both segments, particularly in the competitive wellness market.
Regulatory Landscape
As a bioelectronic medicine company, electroCore’s success is heavily reliant on favorable regulatory developments and reimbursement policies; investor attention will be focused on any updates or concerns shared regarding the evolving regulatory environment.

electroCore Gains Visibility as Vagus Nerve Stimulation Enters Mainstream

Event summary

  • electroCore participated in the documentary 'Hacking the Vagus Nerve,' part of the 'Healing Journeys' series.
  • The documentary features electroCore’s Chief Medical Officer, Peter Staats, and explores the therapeutic potential of vagus nerve stimulation (nVNS).
  • The film highlights electroCore’s gammaCore (migraine), Truvaga Plus (stress management), and TAC-STIM (human performance) products.
  • electroCore has been developing vagus nerve stimulation technologies for over 20 years.

The big picture

The growing interest in the vagus nerve as a therapeutic target represents a significant opportunity for electroCore, positioning the company at the forefront of a nascent bioelectronic medicine market. The documentary’s visibility provides a platform to educate consumers and clinicians, but the company's success hinges on translating awareness into sustained commercial adoption and demonstrating clinical efficacy beyond existing indications. The market for non-invasive neuromodulation is still relatively small, but holds potential for substantial growth as the science matures.

What we're watching

Market Adoption
The documentary's reach and impact on consumer awareness of nVNS will be a key indicator of potential demand for electroCore’s consumer-facing products like Truvaga Plus and TAC-STIM, though conversion from awareness to sales remains uncertain.
Clinical Validation
Continued clinical research supporting the efficacy of nVNS across a broader range of conditions, particularly PTSD and Long COVID, will be crucial for expanding prescription adoption of gammaCore and securing reimbursement.
Competitive Landscape
The increased mainstream attention to vagus nerve stimulation may attract new entrants and intensify competition within the bioelectronic medicine space, requiring electroCore to maintain its technological lead and brand recognition.
CID: 3651